Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)

计划入组 60 人 · 首次发布于 2011 年 9 月 19 日

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine

计划入组 420 人 · 首次发布于 2014 年 1 月 17 日

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children

计划入组 840 人 · 首次发布于 2014 年 6 月 2 日

VXA-G2-4-NS

VXA-GII.4-NS

Bivalent GII.4/GI.1

Xi'an No.4 Hospital

China

Guiyang No.4 People's Hospital

China

Huai'an No.4 People's Hospital

China

Vaxart Advances Second-Generation Norovirus Oral Vaccine with Improved Immune Response Data

Cocrystal Pharma's Antiviral CDI-988 Shows Potent Activity Against Emerging Norovirus Variants

Cocrystal Pharma Advances Antiviral Pipeline with $13M Funding, CDI-988 Enters Phase 1b Human Challenge Study